In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CRISPR Therapeutics AG (NASDAQ: CRSP) closed the day trading at $48.24 down -1.89% from the previous closing price of $49.17. In other words, the price has decreased by -$1.89 from its previous closing price. On the day, 0.77 million shares were traded. CRSP stock price reached its highest trading level at $48.685 during the session, while it also had its lowest trading level at $47.57.
Ratios:
For a better understanding of CRSP, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.73 and its Current Ratio is at 15.73. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on August 06, 2024, Reiterated its Buy rating but revised its target price to $84 from $88 previously.
On August 02, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $90.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 21 ’24 when Bruno Julianne sold 3,366 shares for $56.09 per share. The transaction valued at 188,799 led to the insider holds 6,745 shares of the business.
Kulkarni Samarth sold 19,582 shares of CRSP for $1,173,232 on Apr 15 ’24. The Chief Executive Officer now owns 208,122 shares after completing the transaction at $59.91 per share. On Mar 15 ’24, another insider, Prasad Raju, who serves as the Chief Financial Officer of the company, sold 3,524 shares for $72.69 each. As a result, the insider received 256,160 and left with 6,476 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 4108514048 and an Enterprise Value of 2338195968. For the stock, the TTM Price-to-Sale (P/S) ratio is 20.32 while its Price-to-Book (P/B) ratio in mrq is 2.07. Its current Enterprise Value per Revenue stands at 11.562 whereas that against EBITDA is -6.976.
Stock Price History:
Over the past 52 weeks, CRSP has reached a high of $91.10, while it has fallen to a 52-week low of $37.55. The 50-Day Moving Average of the stock is -10.73%, while the 200-Day Moving Average is calculated to be -22.39%.
Shares Statistics:
Over the past 3-months, CRSP traded about 1.32M shares per day on average, while over the past 10 days, CRSP traded about 1070920 shares per day. A total of 85.17M shares are outstanding, with a floating share count of 81.46M. Insiders hold about 4.35% of the company’s shares, while institutions hold 63.14% stake in the company. Shares short for CRSP as of 1722384000 were 16428259 with a Short Ratio of 13.06, compared to 1719532800 on 15652762. Therefore, it implies a Short% of Shares Outstanding of 16428259 and a Short% of Float of 21.9.
